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Abstract 
One of the two common hallmark lesions of Alzheimer’s disease (AD) brains is neurofibrillary tangles (NFTs), which are 
composed of hyperphosphorylated tau protein (p‑tau). NFTs are also a defining feature of other neurodegenerative 
disorders and have recently been identified in the brains of patients suffering from chronic traumatic encephalopathy 
(CTE). However, NFTs are not normally observed in traumatic brain injury (TBI) until months or years after injury. This 
raises the question of whether NFTs are a cause or a consequence of long‑term neurodegeneration following TBI. Two 
conformations of phosphorylated tau, cis p‑tau and trans p‑tau, which are regulated by the peptidyl‑prolyl isomer‑
ase Pin1, have been previously identified. By generating a polyclonal and monoclonal antibody (Ab) pair capable of 
distinguishing between cis and trans isoforms of p‑tau (cis p‑tau and trans p‑tau, respectively), cis p‑tau was identi‑
fied as a precursor of tau pathology and an early driver of neurodegeneration in AD, TBI and CTE. Histological studies 
shows the appearance of robust cis p‑tau in the early stages of human mild cognitive impairment (MCI), AD and CTE 
brains, as well as after sport‑ and military‑related TBI. Notably, cis p‑tau appears within hours after closed head injury 
and long before other known pathogenic p‑tau conformations including oligomers, pre‑fibrillary tangles and NFTs. 
Importantly, cis p‑tau monoclonal antibody treatment not only eliminates cis p‑tau induction and tau pathology, but 
also restores many neuropathological and functional outcome in TBI mouse models. Thus, cis p‑tau is an early driver of 
tau pathology in TBI and CTE and detection of cis p‑tau in human bodily fluids could potentially provide new diagnos‑
tic and prognostic tools. Furthermore, humanization of the cis p‑tau antibody could ultimately be developed as a new 
treatment for AD, TBI and CTE.
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Background
Tau protein is a member of the microtubule-associated 
family of proteins which are expressed predominantly 
in the brain. Tau’s primary functions, which include the 
stabilization of microtubules and the coordinated move-
ment of molecules along the microtubule, are tightly reg-
ulated by phosphorylation [1–3]. In its native state, tau 
is present in a stable, unfolded monomeric conformation. 
However, via as yet unknown mechanisms, tau becomes 
aberrantly phosphorylated, or hyperphosphorylated, and 
aggregated in several neurodegenerative diseases, collec-
tively known as tauopathies [2, 3].
Although human tau is predominantly expressed in 
neurons, it can also be found in astrocytes and oligo-
dendrocytes [4]. In the central nervous system, alternate 
splicing of exon 2, 3 and 10 leads to the generation of six 
isoforms of tau which range from 352 to 441 amino acids 
in length and 60–74  kDa in weight as determined by 
SDS-PAGE analyses [5]. The variability in these isoforms 
derives from the presence or absence of exon inserts (0, 
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1 or 2) in tau’s N-terminal region and the presence or 
absence of microtubule binding repeat domains in tau’s 
C-terminal region [6]. Highly phosphorylated tau with a 
3-repeat domain in the C-terminus predominates dur-
ing early stages of development whereas a ~ 1:1 ratio of 
3-repeat:4-repeat tau is present in adults. Trace amounts 
of tau are also detectable in peripheral organs such as the 
heart, kidney, lungs, muscle, pancreas and testis but this 
peripheral tau is larger than brain tau with an additional 
N-terminal sequence tau encoded by exon 4A. Thus, it is 
sometimes referred to as ‘big tau’ [6].
Phosphorylation of tau decreases normally with age 
and coincides with the development of phosphatases 
[7]. However, in tauopathies, the aberrant phosphoryla-
tion of tau leads to abnormal accumulations of tau in the 
brain [8]. The most archetypal tau aggregations occur 
in Alzheimer’s disease (AD) in which hyperphosphoryl-
ated tau forms aggregates within the cell bodies known 
as neurofibrillary tangles (NFTs). In addition to AD there 
are several well-established neurodegenerative tauopa-
thies, which include fronto-temporal dementia, Pick’s 
disease, amyotrophic lateral sclerosis (ALS), progres-
sive supranuclear palsy (PSP) and corticobasal dementia 
(CBD) as well as Parkinson’s disease with dementia [9]. 
More recently, abnormal accumulations of tau have been 
associated with chronic traumatic encephalopathy (CTE) 
and traumatic brain injury (TBI), particularly in sports-
related injuries exposing athletes to repeated mild trau-
matic brain injury (rmTBI), with or without concussion, 
and military personnel exposed to repeated explosive 
blast injuries [10–12].
Post‑translational modifications and tau 
aggregation in neurodegenerative diseases
Tau can be post-translationally modified in several ways 
including phosphorylation, acetylation, glycation, prolyl-
isomerization, cleavage or truncation, nitration, poly-
amination, ubiquitination, sumoylation, oxidation and 
aggregation [13–15]. The most well studied of these, and 
arguably one of the most important, is the phosphoryla-
tion of tau [16]. Tau in its dephosphorylated state is not 
prone to aggregation but phosphorylation of tau, which 
is required for regulation of its physiological functions, 
can increase or reduce its stability. Although debate 
continues regarding the contribution of tau to neurode-
generation, there is mounting evidence to suggest that 
the phosphorylation of tau, or more notably the hyper-
phosphorylation of tau, may lead to its increased aggre-
gability, eventually leading to neuropathogenicity such as 
NFTs [17, 18]. In AD, hyperphosphorylated tau in NFTs 
is composed of approximately equal amounts of both 3R 
and 4R tau whereas other diseases are associated with a 
higher ratio of 3R:4R (Pick’s disease) or a higher ratio of 
4R:3R (CBD and PSP). The appearance and localisation 
of tau aggregates in different neurodegenerative diseases 
also varies widely [19, 20].
Hyperphosphorylation of tau
The primary mode of regulation of tau function occurs 
via phosphorylation at specific sites and coordinated 
phosphorylation events are necessary for proper neurite 
outgrowth and axonal transport processes [21]. While 
the exact role of abnormal phosphorylation of tau in 
tauopathies is unclear, there is substantial evidence to 
show that hyperphosphorylation plays a key role in the 
development of AD and a myriad of other neurodegen-
erative diseases associated with pathological tau [18, 
22]. Hyperphosphorylation induces the formation of 
tau aggregates with highly phosphorylated tau showing 
self-assembly in  vitro. Mutations at the Ser422 location 
lead to a significant increase in tau-tau propensity [17]. 
Pre-tangle formation in specific brain regions has been 
shown to hinder memory, disrupt synaptic function, and 
produce a rapid impairment of long-term potentiation 
(LTP). These toxic molecules can also catalyse neuronal 
loss and the accumulation of intracellular neurofibrillary 
tangles (NFTs) composed mainly of tau protein [17, 23]. 
Growing evidence also proposes that these potentially 
neurotoxic conglomerations perhaps act in a prion-like 
manner, but additional research will be required to elu-
cidate their exact mechanism of action [24]. Interestingly, 
hyperphosphorylated tau aggregates reach a neurotoxic 
state prior to the formation of neurofibrillary tangles, 
thus making tau an enticing new target for preventative 
treatments of tau pathology [25]. Along with increased 
tau-tau affinity, hyperphosphorylation has also been cor-
related with a loss of normal tau physiological function. 
Neurons labeled with antibodies to recognize phospho-
Thr231 and phospho-Ser262 [26] display significantly 
decreased normal physiological interactions of tau with 
microtubules upon phosphorylation [25, 27] greatly 
diminishing the ability of this protein to bind to, as well 
as stabilize, microtubules. It is therefore suggested that 
the loss of normal physiological functions, as well as 
the onset of toxic characteristics driven by the aberrant 
phosphorylation of tau, likely contribute synergistically 
to tau pathology.
Tau in traumatic brain injury and chronic traumatic 
encephalopathy
TBI has been identified as a major risk factor for CTE 
and AD, which are characterized by abnormally phos-
phorylated tau aggregates in neurons and glia of multi-
ple brain regions [28, 29]. For example, one in three NFL 
players are expected to experience cognitive problems in 
their lifetime. TBI is a leading cause of death or disability 
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of children and young adults aged 1–44 and also affects 
one in five veterans of the Afghanistan and Iraq conflicts 
[29]. However, pathogenic mechanisms leading from 
acute TBI to chronic neurodegeneration are virtually 
unknown. There is no effective treatment available for 
mitigating secondary injury after acute TBI and prevent-
ing the late development of AD or CTE. Neurofibrillary 
tangles (NFTs) composed of phosphorylated tau are a 
neuropathological hallmark not only of AD but also CTE 
[11, 29]. Furthermore, the tau isoform and hyperphos-
phorylation profiles of tau tangles purified from boxer 
CTE brains and AD brains are indistinguishable [30, 31]. 
Tau in these diseases is commonly hyperphosphorylated 
on Ser or Thr residues, especially those preceding a Pro 
residue (pSer/Thr-Pro) and such phosphorylation pre-
cedes tangle formation and neurodegeneration. However, 
it is not fully understood how phosphorylation causes 
tau, which serves a vital physiologic function in healthy 
neurons, to become pathogenic. Until recently, whether 
tau is further regulated after phosphorylation and if the 
pathogenic phosphorylated tau can be blocked without 
affecting physiological tau were not known.
In rodent models mimicking the effects of TBI, a nota-
ble increase in total tau levels and p-tau pretangle confor-
mations, in conjunction with white matter degradation 
and increased neuroinflammation, have been found 
2–3  months after post-injury [32]. These findings indi-
cate a potential role for tau in the propagation of neuro-
pathology in TBI and illustrate a possible bridge between 
TBI and CTE.
The emergence of a new tau isoform—cis p‑tau
Proline-directed Ser/Thr phosphorylation is a central 
common signaling mechanism in the cell. We have found 
that certain pSer/Thr-Pro motifs exist in cis or trans con-
formations, and their conversion and function is further 
regulated by the unique prolyl isomerase Pin1 [33]. It 
has been shown that Pin1 is pivotal in protecting against 
age-dependent tau aggregation in AD by isomerizing the 
phosphorylated T231-P motif in tau (pT231-tau or p-tau) 
from cis to trans p-tau [33–35]. Furthermore, Pin1 is 
required for the regulated dephosphorylation of tau dur-
ing microtubule stabilisation. Therefore, in the absence of 
Pin1, tau cannot be properly dephosphorylated and the 
ratio of cis p-tau to trans p-tau ratio is increased [33]. 
This discovery indicates that cis p-tau may be pathologi-
cally important and targetable. Normally, more than 90% 
of conventional pT231-tau peptides are in trans p-tau 
conformation [36] and therefore can only be used to 
generate trans mAbs [36, 37], which would likely reduce 
physiological tau. Using novel peptide chemistry, we 
recently generated not only trans p-tau-specific but also 
cis p-tau-specific antibodies which we used to discover 
a previously unrecognized pathogenic cis p-tau which 
appears early-on in the disease process and which is not 
readily or dynamically converted to trans in  vivo in the 
absence of Pin1 [37].
Deficits in the function of Pin1, correlating with an 
increase in cis- p-tau have already been implicated in 
early AD [37, 38]. In particular, Pin1 down-regulation 
[33, 35], Cys113 oxidation [39] and phosphorylation at 
residue S71 [39, 40] have been shown to contribute to the 
aberrant tau function in AD. Down-regulation of Pin1 via 
serum depletion or Cys113 oxidation via hypoxia in cul-
tured neurons correlates well with increases in cis p-tau. 
Pin1 binds to tau primarily at the T231 residue catalys-
ing the conversion from cis to trans p-tau [33, 41]. Since 
the phosphorylation of T231 is also an early step in tan-
gle formation [42], Pin1 plays a critical role in reversing 
phosphorylation, preventing hyperphosphorylation and 
preventing accumulation of cis p-tau [33, 37, 38]. We 
further discovered that cis, but not trans, p-tau appears 
early in the neurons of human brains affected by MCI. 
We found that cis p-tau accumulates exclusively in the 
dystrophic neurites of degenerating neurons as AD 
progresses and correlates well with cognitive deficits 
[38]. Moreover, cis, but not trans, p-tau loses its normal 
microtubule-assembling ability, and gains toxic function, 
being resistant to dephosphorylation and degradation, 
and prone to aggregation [37, 38, 43]. Thus, cis p-tau may 
be a precursor of tau pathologies and an early driver of 
neurodegeneration which may have the potential for neu-
ron-to-neuron transmission in TBI, CTE and AD.
Using cis and trans tau-specific monoclonal antibodies 
it has been possible to show that robust cis p-tau appears 
early in human MCI, AD and CTE brains, as well as 
after sport- and military-related TBI and long before tau 
aggregates or fibrils can be detected [43]. In TBI closed-
head injury mouse models, cis, but not trans, p-tau was 
readily induced at 12 h post-injury and further increased 
with time, localizing mainly to axons leading to axonopa-
thy. This occurred long before commonly other known 
pathological tau, such as fibrillary tau and tau oligomers, 
could be detected. Furthermore, cis p-tau monoclonal 
antibody (mAb) treatment eliminated cis p-tau induc-
tion as well as cis p-tau-induced neurotoxicity in stressed 
neuron models in vitro and in TBI mouse models in vivo 
[43]. Of note, recent studies have shown the presence 
of tau oligomers within 48 h of severe open-head injury 
in mouse models [44], which were not observed in our 
closed-head injury model [43] (and unpublished results). 
Thus, neutralizing mAbs against the early and toxic cis 
p-tau reduce pathological tau without affecting healthy 
trans p-tau, and have the potential to be highly effica-
cious and specific in halting or preventing tau pathol-
ogy and memory loss in TBI, CTE and AD at early stages 
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(Fig. 1). The mechanism by which TBI induces robust cis 
p-tau induction is currently unclear. However, it is likely 
that TBI, as in stroke and AD, causes the induction of the 
stress protein death-activated protein kinase 1 (DAPK1), 
which is responsible for the phosphorylation and inacti-
vation of Pin1 [40]. Therefore, increases in DAPK1 will 
likely cause inactivation of Pin1 and subsequent induc-
tion of cis p-tau.
Discovery of cistauosis and its role in early 
common disease mechanism in TBI, CTE and AD, 
which can be blocked by cis mAb
Immunotherapy against tau is attracting attention 
because active or passive immunization against p-tau 
tangle epitopes reduces the initial formation of patho-
logical tau ‘seeds’ and subsequent spreading of tau 
aggregates. Although extensive tangles are a neuropatho-
logical signature in CTE in sport and military, evidence 
of tau pathology is not readily detectable acutely after 
TBI in humans and mouse models using other com-
monly known antibodies/techniques. However, we found 
robust cis p-tau in human CTE brains. Surprisingly, after 
TBI in mice and stress in vitro, neurons acutely produce 
cis p-tau notable at axons, which disrupts axonal micro-
tubules and axonal mitochondrial transport, spreads to 
other neurons, and leads to apoptosis [43]. This process, 
which we term ‘cistauosis’, appears long before other tau 
oligomers and fibrils but can be blocked by cis mAb and 
enhanced by trans mAb [43]. Treating TBI mice with cis 
mAb blocks early cistauosis, prevents the development 
and spread of tau aggregates such as oligomers and fibrils, 
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Fig. 1 Pin1 prevents the accumulation of the pathogenic cis P‑Tau by converting it to non‑pathogenic trans form. pT231‑tau exists in the two‑
distinct cis and trans conformations, as depicted in cartoons of the primary backbone structures. Cis, but not trans, pT231‑tau loses normal function 
and gains pathogenic function. Pin1 prevents the accumulation of the pathogenic cis pT231‑tau conformation by converting it into the nonpatho‑
genic trans form. Conformation specific antibodies against the pathogenic cis pT231‑tau might be developed for the treatment of AD, MCI, TBI, CTE 
or other kind of tauopathies, during its early stages. AD Alzheimer’s disease; MCI mild cognitive impairment; TBI traumatic brain injury; CTE chronic 
traumatic encephalopathy
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changes. Thus, cis, but not trans, p-tau is a likely patho-
genic form of tau in MCI and AD and the development 
of humanised antibodies directed against pathogenic cis 
p-tau could be useful for the early diagnosis and treat-
ment of AD, TBI and CTE.
Treatments to reduce pathogenic tau isoforms 
in AD, TBI and CTE
Currently there are no effective treatment options for 
patients with AD. Drug trials targeting reduction of the 
amyloid beta deposits have been shown to be efficacious 
in reducing amyloid beta deposits in the brain but there 
has been no convincing evidence that there is improve-
ment in cognitive function [45]. The disappointing results 
from amyloid beta treatment studies has caused a shift in 
focus to the treatment of tau in AD. More recently, CSF 
biomarker studies have indicated that tau is superior to 
amyloid beta markers in following the progression of 
cognitive deficits in AD and other tauopathies [46, 47]. 
Furthermore, a newly developed PET technique to track 
changes in tau deposition in living patients with AD also 
shows that tau deposition more closely tracked demen-
tia status and was a better indicator of cognitive deficits, 
thus indicating that treatments targeting tau could pro-
vide a superior alternative to amyloid beta therapies [45]. 
Several tau-targeting treatments have been trialled, or 
are currently being trialled. Most of these focus primarily 
on kinase inhibition or the inhibition of tau aggregation 
[48].
These strategies are likely to have a huge benefit for the 
treatment of AD and other tauopathies if proven suc-
cessful but may be limited to treating only patients in 
the later stages of disease, especially those targeting tau 
aggregations. Since we find increases in cis p-tau early 
after TBI in both mouse and human brain, humanisa-
tion of our cis p-tau antibody for use as an early therapy 
could prove to be an effective intervention for patients 
early after TBI. Furthermore, it could potentially prevent 
the development of CTE following multiple head trau-
mas. Finally, we have already shown that treatment with 
our cis p-tau antibody in mouse models not only prevents 
the development of neurofibrillary tangles and other tau 
pathologies, it also effectively removes cis p-tau aggrega-
tions and improved cognitive function. Therefore, further 
development and humanisation of the cis p-tau antibody 
also provides a potential new treatment for prevention 
and treatment of AD.
Conclusion
The emergence of cis p-tau as a newly identified patho-
genic isoform of tau presents a new pathway through 
which to develop new diagnostic tests to identify tau 
pathology following TBI, CTE and to identify early stage 
AD. Furthermore, the cis p-tau antibody targets a spe-
cific isoform of pathogenic tau which could ultimately 
be developed into a new treatment method for reduc-
ing tau pathology in AD, TBI and CTE and subsequently 
improving cognitive function in these patients.
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